Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Oncology

How Doctors Determine Your Stage and Liver Health

At a Glance

Treating hepatocellular carcinoma requires managing both the tumor and underlying liver disease. Doctors use the BCLC system, Child-Pugh score, and ALBI grade to measure your liver's strength and determine which cancer treatments are safest and most effective for your specific situation.

Return to Home

Treating Hepatocellular Carcinoma (HCC) is often described as managing “two diseases” at once: the cancer (the tumor) and the underlying liver disease (usually cirrhosis) [1][2]. Because the liver is your body’s chemical factory, doctors cannot simply treat the tumor without first checking if the “factory” is strong enough to handle the treatment [3][4].

To do this, your medical team uses three specific “measuring sticks” to determine your stage and your options.

1. The BCLC Staging System

The Barcelona Clinic Liver Cancer (BCLC) system is the international “roadmap” for HCC care [5]. Unlike other cancers that only look at tumor size, BCLC combines three vital factors [5][6]:

  • The Tumor(s): How many are there, how big are they, and have they spread to blood vessels? [5]
  • Liver Function: How well is the non-cancerous part of the liver working? [7]
  • Performance Status: How do you feel physically? Are you able to carry out daily activities, or do you need to spend more than half the day in bed? [8][9]

Your BCLC stage (from 0/Very Early to D/Terminal) tells the doctor which category of treatment is likely safest and most effective for you [10][11].

2. The Child-Pugh Score

The Child-Pugh (CP) score is the traditional way doctors measure liver “reserve” [12]. It uses five inputs to give you a letter grade [13]:

  • Lab Tests: Bilirubin (bile pigment), Albumin (protein), and INR (how fast your blood clots) [13].
  • Physical Signs: Ascites (fluid buildup in the belly) and Encephalopathy (confusion or “brain fog” caused by the liver) [13].
Class Points Meaning
Class A 5–6 Well-compensated; liver is working well despite the disease [13].
Class B 7–9 Significant functional compromise; the liver is struggling [13].
Class C 10–15 Decompensated; the liver is failing and needs aggressive support [14].

3. The ALBI Grade: A More Objective View

While the Child-Pugh score is widely used, it has a flaw: assessing “confusion” or “mild fluid” can be subjective—different doctors might see it differently [15][16].

The ALBI Grade (Albumin-Bilirubin) was created to fix this. It is a strictly mathematical score that uses only two objective blood tests: Albumin and Bilirubin [15][17].

  • Why it matters: Research shows that ALBI can sometimes find “hidden” liver weakness in patients who seem to be in Child-Pugh Class A [18][19].
  • Grade 1 is the best liver function, while Grade 3 suggests the liver is under significant stress [15].

Why These Scores Decide Your Treatment

These scores help prevent a “cure” from being worse than the disease. For example, if your tumor is small but your ALBI grade is high (poor liver function), surgery might cause the rest of your liver to fail [20][21]. In that case, your team might recommend a transplant or a less invasive “locoregional” treatment instead [22][23].

By looking at your BCLC stage, Child-Pugh class, and ALBI grade together, your doctors can balance the need to kill the cancer with the absolute necessity of keeping your liver working [7][3].

Common questions in this guide

What is the BCLC staging system for liver cancer?
The Barcelona Clinic Liver Cancer (BCLC) system is an international roadmap for HCC care. It determines your stage by evaluating tumor size and spread, your baseline liver function, and your daily physical performance status.
What does my Child-Pugh score mean?
The Child-Pugh score measures how well your liver is functioning. It uses specific blood tests and physical signs, like fluid in the belly, to give your liver a grade of A, B, or C, helping doctors know if it can handle certain cancer treatments.
Why do doctors calculate an ALBI grade?
The ALBI grade is a strictly mathematical score that uses two objective blood tests, albumin and bilirubin, to assess liver health. It helps doctors find hidden liver weakness that other scoring systems might miss.
How does my overall liver health affect my cancer treatment options?
Treating HCC means managing both the cancer and the underlying liver disease. If your liver function is weak, aggressive treatments like surgery could cause liver failure, so doctors use these scores to recommend safer alternatives.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my current Child-Pugh class, and what specific factors (like albumin or bilirubin) are driving that score?
  2. 2.Could you calculate my ALBI grade to see if it provides a more detailed picture of my liver's health?
  3. 3.Based on the BCLC system, what stage is my cancer, and how much of that is due to the tumor versus my liver function?
  4. 4.Does my performance status (physical fitness) limit any of the treatment options we are considering?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Role of Virus-Related Chronic Inflammation and Mechanisms of Cancer Immune-Suppression in Pathogenesis and Progression of Hepatocellular Carcinoma.

    Borgia M, Dal Bo M, Toffoli G

    Cancers 2021; (13(17)) doi:10.3390/cancers13174387.

    PMID: 34503196
  2. 2

    Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression.

    Orci LA, Sanduzzi-Zamparelli M, Caballol B, et al.

    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2022; (20(2)):283-292.e10 doi:10.1016/j.cgh.2021.05.002.

    PMID: 33965578
  3. 3

    Serum soluble Toll-like receptor 4 and the risk of hepatocellular carcinoma in hepatitis C virus patients.

    Elkammah M, Gowily A, Okda T, Houssen M

    Contemporary oncology (Poznan, Poland) 2020; (24(4)):216-220 doi:10.5114/wo.2020.102818.

    PMID: 33531868
  4. 4

    Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma.

    Pecorelli A, Lenzi B, Gramenzi A, et al.

    Liver international : official journal of the International Association for the Study of the Liver 2017; (37(3)):423-433 doi:10.1111/liv.13242.

    PMID: 27566596
  5. 5

    A modified staging of early and intermediate hepatocellular carcinoma based on single tumour >7 cm and multiple tumours beyond up-to-seven criteria.

    Wang YY, Zhong JH, Xu HF, et al.

    Alimentary pharmacology & therapeutics 2019; (49(2)):202-210 doi:10.1111/apt.15074.

    PMID: 30506713
  6. 6

    Staging and Prognostic Models for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.

    Burkhart RA, Pawlik TM

    Cancer control : journal of the Moffitt Cancer Center 2017; (24(3)):1073274817729235 doi:10.1177/1073274817729235.

    PMID: 28975828
  7. 7

    Risk factors of mortality in the patients with hepatocellular carcinoma: A multicenter study in Indonesia.

    Jasirwan COM, Hasan I, Sulaiman AS, et al.

    Current problems in cancer 2020; (44(1)):100480 doi:10.1016/j.currproblcancer.2019.05.003.

    PMID: 31130257
  8. 8

    LIME-based ensemble machine for predicting performance status of patients with liver cancer.

    Nguyen HV, Byeon H

    Digital health 2023; (9()):20552076231211636 doi:10.1177/20552076231211636.

    PMID: 38025102
  9. 9

    Palliative radiotherapy for hepatic tumors: a narrative review of indications and recommendations.

    Pennock M, Klein J, Lock M

    Annals of palliative medicine 2023; (12(6)):1420-1446 doi:10.21037/apm-22-965.

    PMID: 37574583
  10. 10

    Adherence to the modified Barcelona Clinic Liver Cancer guidelines: Results from a high-volume liver surgery center in East Asias.

    Yen YH, Cheng YF, Wang JH, et al.

    PloS one 2021; (16(3)):e0249194 doi:10.1371/journal.pone.0249194.

    PMID: 33765059
  11. 11

    Liver resection of hepatocellular carcinoma within and beyond the Barcelona Clinic Liver Cancer guideline recommendations: Results from a high-volume liver surgery center in East Asia.

    Liu YW, Yong CC, Lin CC, et al.

    Journal of surgical oncology 2020; (122(8)):1587-1594 doi:10.1002/jso.26183.

    PMID: 32815189
  12. 12

    Albumin-Bilirubin Grade and Hepatocellular Carcinoma Treatment Algorithm.

    Kudo M

    Liver cancer 2017; (6(3)):185-188 doi:10.1159/000462199.

    PMID: 28626730
  13. 13

    Assessing the risk of surgery in patients with cirrhosis.

    Kaltenbach MG, Mahmud N

    Hepatology communications 2023; (7(4)) doi:10.1097/HC9.0000000000000086.

    PMID: 36996004
  14. 14

    Oesophageal Varices And Associated Factors In Cirrhotic Patients With Hepatitis C.

    Ali SM, Farrukh SZUI, Haqqi SAUH, et al.

    Journal of Ayub Medical College, Abbottabad : JAMC 2022; (34(4)):834-837 doi:10.55519/JAMC-04-10746.

    PMID: 36566409
  15. 15

    Integration of albumin-bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma.

    Chan AW, Kumada T, Toyoda H, et al.

    Journal of gastroenterology and hepatology 2016; (31(7)):1300-6 doi:10.1111/jgh.13291.

    PMID: 26751608
  16. 16

    Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade.

    Toyoda H, Lai PB, O'Beirne J, et al.

    British journal of cancer 2016; (114(7)):744-50 doi:10.1038/bjc.2016.33.

    PMID: 27022825
  17. 17

    A multicentre comparison between Child Pugh and Albumin-Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma.

    Edeline J, Blanc JF, Johnson P, et al.

    Liver international : official journal of the International Association for the Study of the Liver 2016; (36(12)):1821-1828 doi:10.1111/liv.13170.

    PMID: 27214151
  18. 18

    Comparison between Child-Pugh score and Albumin-Bilirubin grade in the prognosis of patients with HCC after liver resection using time-dependent ROC.

    Zhao S, Wang M, Yang Z, et al.

    Annals of translational medicine 2020; (8(8)):539 doi:10.21037/atm.2020.02.85.

    PMID: 32411762
  19. 19

    Comparison of albumin-bilirubin grade versus Child-Pugh score in predicting the outcome of transarterial chemoembolization for hepatocellular carcinoma using time-dependent ROC.

    Zhao S, Zhang T, Li H, et al.

    Annals of translational medicine 2020; (8(8)):538 doi:10.21037/atm.2020.02.124.

    PMID: 32411761
  20. 20

    Comparison between Child-Pugh Score and albumin-bilirubin grade in patients treated with the combination therapy of transarterial chemoembolization and sorafenib for hepatocellular carcinoma.

    Wang Z, Fan Q, Wang M, et al.

    Annals of translational medicine 2020; (8(8)):537 doi:10.21037/atm.2020.02.114.

    PMID: 32411760
  21. 21

    Albumin-bilirubin grade predicts the outcomes of liver resection versus radiofrequency ablation for very early/early stage of hepatocellular carcinoma.

    Chong CC, Chan AW, Wong J, et al.

    The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland 2018; (16(3)):163-170 doi:10.1016/j.surge.2017.07.003.

    PMID: 28807570
  22. 22

    Liver transplant offers a survival benefit over margin negative resection in patients with small unifocal hepatocellular carcinoma and preserved liver function.

    Benjamin AJ, Baker TB, Talamonti MS, et al.

    Surgery 2018; (163(3)):582-586 doi:10.1016/j.surg.2017.12.005.

    PMID: 29370929
  23. 23

    The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy.

    Galle PR, Tovoli F, Foerster F, et al.

    Journal of hepatology 2017; (67(1)):173-183 doi:10.1016/j.jhep.2017.03.007.

    PMID: 28323121

This page explains HCC staging and liver function scores for educational purposes only. Always consult your oncologist or hepatologist to understand your specific stage, scores, and treatment options.

Get notified when new evidence is published on Hepatocellular carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.